Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 14/20 | 0.47 |
| ▸ | TSHR | P16473 | 10/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 7/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | CTSK | P43235 | 4/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7950561 | 0.84 | SYK (0.48) | CYP3A4TSHRALDH1A1SMN1; SMN2CASP1 | |
| SCHEMBL1558488 | 0.81 | ATM (0.47) | CYP3A4TSHRALDH1A1SMN1; SMN2CASP1 | |
| SCHEMBL2243262 | 0.81 | SYK (0.46) | CYP3A4TSHRALDH1A1SMN1; SMN2CASP1 | |
| SCHEMBL5605686 | 0.76 | CASP1 (0.51) | CYP3A4TSHRALDH1A1SMN1; SMN2CASP1 | |
| SCHEMBL5605395 | 0.75 | CASP1 (0.50) | CYP3A4TSHRALDH1A1SMN1; SMN2CASP1 | |
| SCHEMBL29365807 | 0.75 | CTSK (0.50) | CYP3A4TSHRALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL5605738 | 0.74 | CYP3A4 (0.48) | CYP3A4TSHRALDH1A1SMN1; SMN2CASP1 | |
| SCHEMBL30772669 | 0.74 | ALDH1A1 (0.50) | TSHRALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL23476693 | 0.74 | ALDH1A1 (0.46) | TSHRALDH1A1SMN1; SMN2CYP2C19 | |
| SCHEMBL23460666 | 0.74 | ALDH1A1 (0.46) | TSHRALDH1A1SMN1; SMN2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2313374-B1 | 6-SUBSTITUTED ISOQUINOLINES AND ISOQUINOLINONES | SANOFI SA (FR) | 2013-09-18 | — | — | EP | disclosed |
| EP-2313374-B1 | 6-SUBSTITUTED ISOQUINOLINES AND ISOQUINOLINONES | SANOFI SA (FR) | 2013-09-18 | — | — | EP | disclosed |
| US-20130109715-A1 | 6-Substituted isoquinolines and isoquinolinones | SANOFI (FR) | 2013-05-02 | — | — | US | disclosed |
| US-20130109715-A1 | 6-Substituted isoquinolines and isoquinolinones | SANOFI (FR) | 2013-05-02 | — | — | US | disclosed |
| US-8399482-B2 | 6-substituted isoquinolines and isoquinolinones | SANOFI (FR) | 2013-03-19 | — | — | US | disclosed |
| US-8399482-B2 | 6-substituted isoquinolines and isoquinolinones | SANOFI (FR) | 2013-03-19 | — | — | US | disclosed |
| US-20110190339-A1 | 6-SUBSTITUTED ISOQUINOLINES AND ISOQUINOLINONES | SANOFI-AVENTIS (FR) | 2011-08-04 | — | — | US | disclosed |
| US-20110190339-A1 | 6-SUBSTITUTED ISOQUINOLINES AND ISOQUINOLINONES | SANOFI-AVENTIS (FR) | 2011-08-04 | — | — | US | disclosed |
| EP-2313374-A1 | 6-SUBSTITUTED ISOQUINOLINES AND ISOQUINOLINONES | Sanofi-Aventis (FR) | 2011-04-27 | — | — | EP | disclosed |
| WO-2009156099-A1 | 6-SUBSTITUTED ISOQUINOLINES AND ISOQUINOLINONES | SANOFI-AVENTIS (FR) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009156099-A1 | 6-SUBSTITUTED ISOQUINOLINES AND ISOQUINOLINONES | SANOFI-AVENTIS (FR) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190339-A1 | 6-SUBSTITUTED ISOQUINOLINES AND ISOQUINOLINONES | MYLK2, MYLK, MYLK3 | CYP3A4 3402/4885TSHR 4595/4885ALDH1A1 2573/4885 |
| US-20130109715-A1 | 6-Substituted isoquinolines and isoquinolinones | MYLK2, MYLK, MYLK3 | CYP3A4 3598/4885TSHR 4168/4885ALDH1A1 2500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.